Immunome Inc Stock

$9.91

11.09% yesterday

Nasdaq, Nov 15, 10:18 pm CET

ISIN

US45257U1088

Symbol

IMNM

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Immunome Inc Stock price

$9.91

-3.55 26.36% 5Y

Nasdaq, Closing price Fri, Nov 15 2024

-1.24 11.09%

ISIN

US45257U1088

Symbol

IMNM

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$594.84m
Enterprise Value	$357.43m
P/E (TTM) P/E ratio	negative
EV/Sales (TTM) EV/Sales	35.28
P/S ratio (TTM) P/S ratio	58.72
P/B ratio (TTM) P/B ratio	2.78
Revenue growth (TTM) Revenue growth	-0.62%
Revenue (TTM) Revenue	$10.13m
EBIT (operating result TTM) EBIT	$-310.78m
Cash position	$278.35m
EPS (TTM) EPS	$-8.12
P/E forward	negative
P/S forward	72.28
EV/Sales forward	42.51
Short interest	17.74%

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Get Started for Free Today

Immunome Inc Stock Analysis

Unlock Scores for Free

??

7 Analysts have issued a Immunome Inc forecast:

7x Buy

100%

More details on Analyst Estimates Including Price Targets

7 Analysts have issued a Immunome Inc forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Immunome Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	10 10	1% 1% 100%
- Direct Costs	- -	- -
Gross Profit	8.37 8.37	12% 12% 83%
- Selling and Administrative Expenses	- -	- -
- Research and Development Expense	289 289	1,586% 1,586% 2,849%
EBITDA	- -	- -
- Depreciation and Amortization	1.76 1.76	141% 141% 17%
EBIT (Operating Income) EBIT	-311 -311	1,271% 1,271% -3,068%
Net Profit	-305 -305	1,290% 1,290% -3,014%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Immunome Inc Stock News

Neutral

Business Wire

●

2 days ago

Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update.

Neutral

Business Wire

●

11 days ago

Immunome to Present at Guggenheim's Inaugural Healthcare Innovation Conference

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will participate in a fireside chat at Guggenheim's Inaugural Healthcare Innovation Conference on Wednesday, November 13th at 10:30am Eastern Time. Interest...

Neutral

Business Wire

●

14 days ago

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on October 31, 2024, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purc...

More Immunome Inc News

Company Profile

Immunome, Inc. operates as a transformative immuno-oncology company. It creates new, safe, and powerful cancer therapies by targeting stem cell and universal cancer antigens. The firm offers discovery engine that enables the simultaneous discovery of novel tumor antigens and the cognate native human antibodies that target those antigens. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Exton, PA.

Head office	United States
CEO	Clay Siegall
Employees	55
Founded	2006
Website	www.immunome.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now